February 18, 2019/Cancer/Radiation Oncology

Accelerated Partial Breast Irradiation Offers Best Value After Breast-Conserving Surgery

Similar outcomes at lower cost than hypofractionated whole breast irradiation


It has been a debate for more than a decade: Is accelerated partial breast irradiation (APBI) as effective as hypofractionated whole breast irradiation (HWBI) in treating early-stage breast cancer? Multiple randomized trials have reported very little difference in local recurrence outcomes.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

“Many radiation oncologists now view the two treatments as equally effective based on NSABP B-39 and RAPID as well as previous trials,” says Chirag Shah, MD, Director of Clinical Research and Breast Radiation Oncology in Cleveland Clinic’s Department of Radiation Oncology.

But when it comes to cost, the debate continues. APBI — including advanced techniques like brachytherapy, intensity modulated radiation therapy (IMRT) and stereotactic body radiation therapy (SBRT) — is typically viewed as more expensive. The more advanced the technology, the higher the price tag, right?

Not necessarily, says Dr. Shah, whose recent study in the International Journal of Radiation Oncology • Biology • Physics (the Red Journal) compared the cost-effectiveness of image-guided APBI and HWBI after breast-conserving surgery.

“We’ve been able to show that if we use advanced technology in a way that reduces the number of treatments, the cost is less,” he says. “With image-guided APBI, we can offer outcomes comparable to whole breast irradiation with fewer side effects and at a lower cost for health systems, payers and patients.”

APBI saves $2,591 per patient

During the study, Dr. Shah and colleagues analyzed the cost-effectiveness of HWBI (40 Gy in 15 fractions with or without a 10-Gy/5-fraction boost) and a 30-Gy/5-fraction IMRT regimen. A 2015 randomized study in Italy already had demonstrated similar clinical outcomes and toxicities between the two techniques.


Using microcosting — evaluating detailed costs of personnel time, software, hardware and supplies — each technique was assessed a dollar amount. Indirect costs, such as patients’ travel expenses and lost work time, also were assessed.

The researchers found that, in women age 40 and older with low-risk breast cancer who had breast-conserving surgery, the direct cost of APBI was $1,585 less than HWBI with the boost (and $700 less without the boost). When indirect costs were included, APBI was $2,591 less than HWBI with the boost (and $1,371 less without the boost).

In addition to being the less costly radiation therapy, APBI was found to be more effective based on quality-adjusted life years. Within 90 days of receiving breast irradiation, women receiving APBI recorded 0.2300 quality-adjusted life years compared to 0.2289 for women receiving HWBI with or without boost.

High-tech at a value

“There often is skepticism about the cost-effectiveness of new technologies,” says Dr. Shah. “Many times, payers want to know how we justify the cost and if the technique is worth it. This study showed that IMRT used for APBI is a safe and appropriate technique and can be used in a way that is value-oriented.”


That should resonate well with a healthcare industry now more focused on value-based care. With breast cancer treatment accounting for the highest amount of cancer care costs in the U.S. ($16.5 billion of the $125 billion total in 2010), IMRT APBI can offer excellent outcomes at a significant savings. According to Dr. Shah, the savings could reach $1.4 to 2.6 million (in direct and indirect costs) per 1,000 patients treated with IMRT APBI instead of HWBI.

“IMRT APBI should be considered a standard-of-care option in appropriately selected patients based on efficacy and value,” says Dr. Shah.

Photo Credit: Russell Lee

Related Articles

November 22, 2023/Cancer/Radiation Oncology
A Germline Biomarker Offers Insight Into Treatment Selection for Men With Prostate Cancer

Correlation found between the biomarker HSD3B1 and resistance to combined hormone therapy and radiotherapy

23-CNR-4164208 ASTRO 2023 graphic CQD
September 21, 2023/Cancer/Radiation Oncology
Top 10 Presentations You Don’t Want to Miss at ASTRO 2023

Highlighting top abstracts for the annual radiation oncology conference

23-CNR-3964459-CQD-Hero-650×450 SBRT
New Study Highlights Potential Benefits of Ultrasound-Guided Prostate SBRT

Transperineal ultrasound a viable, non-invasive option for monitoring intra-fractional prostate motion

ASTRO 2022 abstracts
November 4, 2022/Cancer/Radiation Oncology
Top Research from ASTRO 2022

Key abstracts highlight advances in treating locally advanced and refractory disease

radiation therapy
October 14, 2022/Cancer/Radiation Oncology
Radiation Oncology-Biology Integration Network (ROBIN) Explores Precision Medicine

Multidisciplinary team to examine radiation therapy combined with immunotherapy

March 17, 2022/Cancer/Radiation Oncology
Aggressive Daily Radiation in Breast Cancer Survivor with Angiosarcoma: A Case Study

Preoperative treatment ensures successful surgical resection

Squamous Cell carcinoma under microscopy
December 2, 2021/Cancer/Radiation Oncology
Study Identifies Prognostic Subgroups in Cutaneous Squamous Cell Carcinoma

Modification of traditional staging factors associated with survival in high-risk disease